Last reviewed · How we verify
NCT05761938
A Study of Rituximab in Frontline Therapy for Glomerulonephritis
trial in Glomerulonephritis in 100 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 February 2023 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2025 |
| Sites | 5 locations across China |
Conditions studied
- Glomerulonephritis — all drugs for Glomerulonephritis →
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Who can join
Adults 18 to 80, any sex, with Glomerulonephritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study included patients with glomerulonephritis who planned to receive rituximab treatment, and observed the efficacy and safety of rituximab in different glomerulonephritis in the real world. According to the pathological types of glomerulonephritis, they were divided into two cohorts : membranous nephropathy ( MN ) group or minimal change disease / focal segmental glomerulosclerosis ( MCD / FSGS ) group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05761938
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glomerulonephritis
Currently open trials in the same condition.
- NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
- NCT06835322 — Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis · Phase 2 · recruiting
- NCT04662723 — Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. · Phase 4 · recruiting
- NCT05434325 — TESTING -ON Post-Trial ObservatioNal Cohort Study · recruiting
- NCT04663204 — A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropath · Phase 2 · active not recruiting
Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials
Trials by the same sponsor.
- NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
- NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
- NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
- NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
- NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05761938 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Last refreshed: 9 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05761938.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing